Is RARE a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on New gene therapy launches, with revenue (ttm) at ~$717M (2026 guidance $730M-$760M, excluding launches). The bear case rests on ultragenyx remains unprofitable, with a net loss of about $586 million over the trailing twelve months and, per Yahoo Finance, about $292 million of cash against about $1.2 billion of debt as of June 30, 2026, so continued spending or slow launches could pressure the balance sheet and raise dilution or financing risk. Analysts covering it are spread from $16.00 to $39.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Ultragenyx remains unprofitable, with a net loss of about $586 million over the trailing twelve months and, per Yahoo Finance, about $292 million of cash against about $1.2 billion of debt as of June 30, 2026, so continued spending or slow launches could pressure the balance sheet and raise dilution or financing risk. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $16.00, +10.0% from the $14.54 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

New gene therapy launches. Both gene therapies that were under FDA review are now approved: Genglycos (DTX401) for glycogen storage disease type Ia received accelerated approval in August 2026, and Fayuvi (UX111) for Sanfilippo syndrome type A followed in September 2026. The most optimistic analyst target on RARE is $39.00, +168.2% from the $14.54 price. That figure is only reachable if this thesis works close to its best case.

Ultragenyx remains unprofitable, with a net loss of about $586 million over the trailing twelve months and, per Yahoo Finance, about $292 million of cash against about $1.2 billion of debt as of June 30, 2026, so continued spending or slow launches could pressure the balance sheet and raise dilution or financing risk. The voucher sales (about $413 million combined before the NIH share) ease that pressure but are one-time. Value is still concentrated in binary events, especially the GTX-102 Angelman program, and a single negative outcome could sharply move the stock; the roughly 48% decline over the three months to mid-October 2026 shows how severe those moves can be. Rare-disease revenue depends on small patient counts, payer reimbursement, and diagnosis rates, all of which can disappoint, which matters more now that two new gene therapies must find patients. The company faces well-capitalized competitors in gene therapy and orphan drugs, including BioMarin, Sarepta, and larger players. Finally, the 2027 profitability target is a management objective, not a guarantee, and could slip. The most pessimistic published target is $16.00, +10.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Ultragenyx Pharmaceutical (NASDAQ: RARE) develops and sells treatments for rare and ultra-rare genetic diseases, conditions with small patient populations and often no approved the

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (New gene therapy launches) stalling in the reported numbers rather than in the narrative, the risk above (ultragenyx remains unprofitable, with a net loss of about $586 million over the trailing twelve months and, per Yahoo Finance, about $292 million of cash against about $1.2 billion of debt as of June 30, 2026, so continued spending or slow launches could pressure the balance sheet and raise dilution or financing risk) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Ultragenyx develops and commercializes treatments for rare and ultra-rare genetic diseases. Its products are led by Crysvita, and in 2026 it added two gene therapies, Genglycos for glycogen storage disease type Ia and Fayuvi for Sanfilippo syndrome type A, for six FDA approvals in total, while advancing other candidates such as GTX-102 for Angelman syndrome.

No. As of October 2026 Ultragenyx was not profitable, with a net loss of about $586 million over the trailing twelve months, though the Q2 2026 loss of about $92 million was much smaller than earlier quarters. Management has stated a goal of reaching profitability in 2027, and analysts expect a small profit that year, but that is an objective rather than a certainty.

Full-year 2025 revenue was about $673 million, roughly 20% growth, and first-half 2026 revenue was about $350 million, up 14%, with Q2 2026 at about $214 million. TTM revenue is about $717 million. The company's 2026 guidance of $730 million to $760 million excludes the new gene therapy launches.